A Glycopeptide Mosaic Vaccine Elicits Robust Antitumor Immunity by Targeting Glycan Heterogeneity.

ABSTRACT: Aberrantly glycosylated membrane proteins represent promising targets for cancer immunotherapy. However, glycan diversity and heterogeneity pose a challenge to developing effective vaccines against tumors expressing different glycoantigens. To broaden the immune response and enhance the vaccine's efficacy by targeting a wide variety of glycosylation patterns on tumor cells, herein we developed a Mosaic glycopeptide vaccine by simultaneously presenting three different glycopeptides on the carrier protein tetanus toxoid (TT). Immunological evaluation revealed that the Mosaic vaccine elicited higher antibody titers than single-glycopeptide formulations, primarily mediating tumor cell lysis via antibody-dependent cellular cytotoxicity (ADCC) and significantly suppressing tumor growth in both w

SUBMITTER: Wu Y 

PROVIDER: S-EPMC12848700 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature